Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 91-104 , March 2003

Urogenital effects of hormone therapy

  • Dudley Robinson, MRCOG (Sub-Specialty Trainee—Urogynaecology)

      Affiliations

    • Corresponding Author InformationCorresponding author.

References 

  1. Cardozo LD. Role of estrogens in the treatment of female urinary incontinence. Journal of the American Geriatric Society. 1990;38:326–328
  2. Iosif S, Batra S, Ek A, Astedt B. Oestrogen receptors in the human female lower urinary tract. American Journal of Obstetrics and Gynecology. 1981;141:817–820
  3. Batra SC, Fossil CS. Female urethra, a target for oestrogen action. Journal of Urology. 1983;129:418–420
  4. Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. Journal of Urology. 1987;138:130–134
  5. Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstetricia et Gynecologica Scandinavica. 1984;63:257–260
  6. The lower urinary tract in peri- and postmenopausal women. In:  Cardozo LD,  Tapp A,  Versi E editor. The urogenital defiency syndrome. Bagsverd, Denmark: Novo Industri AS; 1987;p. 10–17
  7. Thomas TM, Plymat KR, Blannin J, et al.  Prevalence of urinary incontinence. British Medical Journal. 1980;281:1243–1245
  8. Beato M, Herrich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell. 1995;83:851–857
  9. Green S, Walter P, Kumar V, et al.  Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA. Nature. 1986;320:134–139
  10. Kuiper G, Enmark E, Pelto-Huikko M, et al.  Cloning of a novel oestrogen receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the USA. 1996;93:5925–5930
  11. Warner M, Nilsson S, Gustafsson JA. The oestrogen receptor family. Current Opinion in Obstetrics and Gynecology. 1999;11:249–254
  12. Blakeman PJ, Hilton P, Bulmer JN. Mapping oestrogen and progesterone receptors throughout the female lower urinary tract. Neurourology and Urodynamics. 1996;15:324–325
  13. Ingelman-Sundberg A, Rosen J, Gustafsson SA. Cytosol oestrogen receptors in urogenital tissues in stress incontinent women. Acta Obstetricia et Gynecologica Scandinavica. 1981;60:585–586
  14. Bernstein IT. The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultasonography with reference to the effect of pelvic floor training. Oestrogen receptor studies. Neurourology and Urodynamics. 1997;16(4):237–275
  15. Chen GD, Oliver RH, Leung BS, et al.  Oestrogen receptor α and β expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertility and Sterility. 1999;71:1099–1102
  16. Screiter F, Fuchs P, Stockamp K. Oestrogenic sensitivity of α receptors in the urethral musculature. Urology International. 1976;31:13–19
  17. Blakeman PJ, Hilton P, Bulmer JN. Androgen receptors in the female lower urinary tract. International Urogynaecology Journal. 1997;8:S54
  18. Pang X, Cotreau-Bibbo MM, Sant GR, Theoharides TC. Bladder mast cell expression of high affinity oestrogen receptors in receptors in patients with interstitial cystitis. British Journal of Urology. 1995;75:154–161
  19. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU International. 2000;86:32–38
  20. Rud T, Anderson KE, Asmussen M, et al.  Factors maintaining the urethral pressure in women. Investigative Urology. 1980;17:343–347
  21. Kinn AC, Lindskog M. Oestrogens and phenylpropanolamine in combination for stress incontinence. Urology. 1988;32:273–280
  22. Matsubara S, Okada H, Shirakawa , et al.  Oestrogen levels influence beta-3-adrenoceptor-mediated relaxation of the femal rat detrusor muscle. Urology. 2002;59:621–625
  23. Smith PJB. The effect of oestrogens on bladder function in the female. In:  Campbell S editors. The Management of the Menopause and Postmenopausal Years. Carnforth: MTP; 1976;p. 291–298
  24. Samsioe G, Jansson I, Mellstrom D, Svandborg A. Occurance, nature and treatment of urinary incontinence in a 70 year old female population. Maturitas. 1985;7:335–342
  25. Blakeman PJ, Hilton P, Bulmer JN. Cellular proliferation in the female lower urinary tract with reference to oestrogen status. British Journal of Obstetrics and Gynaecology. 2001;8:813–816
  26. Hextall A, Bidmead J, Cardozo L, Hooper R. Hormonal influences on the human female lower urinary tract: a prospective evaluation of the effects of the menstrual cycle on symptomatology and the results of urodynamic investigation. Neurourology and Urodynamics. 1999;18:282–283
  27. van Geelen JM, Doesburg WH, Thomas CMG. Urodynamic studies in the normal menstrual cycle: the relationship between hormonal changes during the menstrual cycle and the urethral pressure profile. American Journal of Obstetrics and Gynecology. 1981;141:384–392
  28. Benness C, Gangar K, Cardozo LD, Cutner A. Do progestogens exacerbate urinary incontinence in women on HRT?. Neurourology and Urodynamics. 1991;10:316–318
  29. Elliot RA, Castleden CM. Effect of progestagens and oestrogens on the contractile response of rat detrusor muscle to electrical field stimulation. Clinical Science. 1994;87:342
  30. Maggi A, Perez J. Role of female gonadal hormones in the CNS. Life Sciences. 1985;37:893–906
  31. Batra S, Anderson KE. Oestrogen induced changes in muscarinic receptor density and contractile responses in the female rat urinary bladder. Acta Physiologica Scandinavica. 1989;137:135–141
  32. Elliott RA, Castleden CM, Miodrag A, Kirwan P. The direct effects of diethylstilboestrol and nifedipine on the contractile responses of isolated human and rat detrusor muscles. European Journal of Clinical Pharmacology. 1992;43:149–155
  33. Shenfield OZ, Blackmore PF, Morgan CW, et al.  Rapid effects of oestriol and progesterone on tone and spontaneous rhythmic contractions of the rabbit bladder. Neurourology and Urodynamics. 1998;17:408–409
  34. Fantl JA, Wyman JF, Anderson RL, et al.  Post menopausal urinary incontinence: comparison between non-oestrogen and oestrogen supplemented women. Obstetrics and Gynaecology. 1988;71:823–828
  35. Rud T. The effects of oestrogens and gestogens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstetricia et Gynecologica Scandinavica. 1980;59:270–365
  36. Ganger KF, Vyas S, Whitehead RW, et al.  Pulsitility index in the internal carotid artery in relation to transdermal oestradiol and time since the menopause. Lancet. 1991;338:839–842
  37. Jackson S, Vyas S. A double blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index. British Journal of Obstetrics and Gynaecology. 1998;105:408–412
  38. Versi E, Cardozo LD. Urethral instability: diagnosis based on variations in the maximum urethral pressure in normal climateric women. Neurourology and Urodynamics. 1986;5:535–541
  39. Jackson S, Avery N, Shepherd A, et al.  The effect of oestradiol on vaginal collagen in postmenopausal women with stress urinary incontinence. Neurourology and Urodynamics. 1996;15:327–328
  40. Ulmsten U, Ekman G, Giertz G. Different biochemical composition of connective tissue in continent and stress incontinent women. Acta Obstetricia et Gynecologica Scandinavica. 1987;66:455
  41. Diokno AC, Brook BM, Brown MB. Prevalence of urinary incontinence and other urological symptoms in the non-institutionalised elderly. Journal of Urology. 1986;136:1022
  42. Yarnell J, Voyle G, Richards C, Stephenson T. The prevalence and severity of urinary incontinence in women. Journal of Epidemiology and Community Health. 1981;35:71–74
  43. Ouslander JG. Urinary incontinence in nursing homes. Journal of the American Geriatric Society. 1990;38:289–291
  44. MacLennan AH, Taylor AW, Wilson AW, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity, and mode of delivery. British Journal of Obstetrics and Gynaecology. 2000;107:1460–1470
  45. Kok AL, Voorhorst FJ, Burger CW, et al.  Urinary and faecal incontinence in community residing elderly women. Age and Ageing. 1992;21:211
  46. The Hormones and Urogenital Therapy Committee Fantl JA, Cardozo LD, McClish DK. Oestrogen therapy in the management of incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynaecology. 1994;83:12–18
  47. Zullo MA, Oliva C, Falconi G, et al.  Efficacy of oestrogen therapy in urinary incontinence. A meta-analytic study. Minerva Ginecol. 1998;50:199–205
  48. Grady D, Brown JS, Vittinghoff E, et al.  Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstetrics and Gynaecology. 2001;97:116–120
  49. Ouslander JG, Greendale GA, Uman G, et al.  Effects of oral oestrogen and progestin on the lower urinary tract among female nursing home residents. American Geriatric Society. 2001;49(6):803–807
  50. Caine M & Raz S. The role of female hormones in stress incontinence. Proceedings of the 16th Congress of the International Society of Urology. Amsterdam, The Netherlands.
  51. Rud T. The effects of oestrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstetricia et Gynecologica Scandinavica. 1980;59:265–270
  52. Wilson PD, Faragher B, Butler B, et al.  Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. British Journal of Obstetrics and Gynaecology. 1987;94:568–574
  53. Walter S, Wolf H, Barlebo H, Jansen H. Urinary incontinence in postmenopausal women treated with oestrogens: a double-blind clinical trial. Urology International. 1978;33:135–143
  54. Fantl JA, Bump RC, Robinson D, et al.  Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstetrics and Gynaecology. 1996;88:745–749
  55. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. British Journal of Obstetrics and Gynaecology. 1999;106:711–718
  56. Sultana CJ, Walters MD. Oestrogen and urinary incontinence in women. Maturitas. 1995;20:129–138
  57. Beisland HO, Fossberg E, Moer A, et al.  Urethral insufficiency in post-menopausal females: treatment with phenylpropanolamine and oestriol separately and in combination. Urology International. 1984;39:211–216
  58. Hilton P, Tweddel AL, Mayne C. Oral and intravaginal oestrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. International Urogynecology Journal. 1990;12:80–86
  59. Samsioe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta Obstetricia et Gynecologica Scandinavica. 1985;93:57
  60. Cardozo LD, Rekers H, Tapp A, et al.  Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47–53
  61. Nilsson K, Heimer G. Low dose oestradiol in the treatment of urogenital oestrogen deficiency—a pharmacokinetic and pharmacodynamic study. Maturitas. 1992;15:121–127
  62. Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. International Urogynaecology Journal. 1992;3:281
  63. Eriksen PS, Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. European Journal of Obstetrics, Gynaecology and Reproductive Biology. 1992;44:137–144
  64. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. British Journal of Obstetrics and Gynaecology. 2000;107:1029–1034
  65. HUT Committee, 2001. Submitted to International Urogynaecology Journal of Pelvic Floor Dysfunction.
  66. Iosif CS. Effects of protracted administration of oestriol on the lower genitourinary tract in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica. 1992;251:115–120
  67. American National Institute of Health Population Figures. US Treasury Department. NIH. 1991.
  68. Research on the menopause in the 1990s. Report of a WHO Scientific Group. In WHO Technical Report Series 866 Geneva, Switzerland, 1994.
  69. Barlow D, Samsioe G, van Geelan H. Prevalence of urinary problems in European countries. Maturitas. 1997;27:239–248
  70. Greendale GA, Judd JL. The menopause: health implications and clinical management. Journal of the American Geriatric Society. 1993;41:426–436
  71. Samsioe G, Jansson I, Mellstrom D, Svanborg A. The occurrence, nature and treatment of urinary incontinence in a 70 year old population. Mauturitas. 1985;7:335–343
  72. van Geelen JM, van de Weijer PH, Arnolds HT. Urogenital symptoms and resulting discomfort in non-institutionalised Dutch women aged 50–75 years. International Urogynecology Journal of Pelvic Floor Dysfunction. 2000;11:9–14
  73. Versi E, Harvey MA, Cardozo L, et al.  Urogenital prolapse and atrophy at menopause: a prevalence study. International Urogynecology Journal of Pelvic Floor Dysfunction. 2001;12:107–110
  74. Davila GW, Karapanagiotou I, Woodhouse S, et al.  Are women with urogenital atrophy syymptomatic?. Obstetrics Gynaecoloy. 2001;4(supplement 1):S48
  75. Samicoe G. Urogenital ageing—a hidden problem. American Journal of Obstetrics and Gynecology. 1998;178:S245–S249
  76. Mettler L, Olsen PG. Long term treatment of atrophic vaginitis with low dose oestradiol vaginal tablets. Maturitas. 1991;14:23–31
  77. Smith P, Heimer G, Lindskog , Ulmsten U. Oestradiol releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas. 1993;16:145–154
  78. Smith RJN, Studd JWW. Recent advances in hormone replacement therapy. British Journal of Hospital Medicine. 1993;49:799–809
  79. Cardozo LD, Bachmann G, McClish D, et al.  Meta-analysis of oestrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynaecology. 1998;92:722–727
  80. Henriksson L, Stjernquist M, Boquist L, et al.  A one-year multicentre study of efficacy and safety of a continuous, low dose, oestradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. American Journal of Obstetrics and Gynecology. 1996;174:85–92
  81. Bachmann G. Oestradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the last decade. Journal of Reproductive Medicine. 1998;43:991–998
  82. Ayton RA, Darling GM, Murkies AL, et al.  A comparative study of safety and efficacy of low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal vaginal atrophy. British Journal of Obstetrics and Gynaecology. 1996;103:351–358
  83. Brandberg A, Mellstrom D, Samsioe G. Low dose oral oestriol treatment in elderly women with urogenital infections. Acta Obstetricia et Gynecologica Scandinavica. 1987;140:33–38
  84. Parsons CL, Schmidt JD. Control of recurrent urinary tract infections in postmenopausal women. Journal of Urology. 1982;128:1224–1226
  85. Privette M, Cade R, Peterson J, et al.  Prevention of recurrent urinary tract infections in postmenopausal women. Nephron. 1988;50:24–27
  86. Kjaergaard B, Walter S, Knudsen A, et al.  Treatment with low dose vaginal oestradiol in postmenopausal women. A double blind controlled trial. Ugeskr Laeger. 1990;152:658–659
  87. Raz R, Stamm WE. A controlled trial of intravaginal oestriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine. 1993;329:753–756
  88. Kirkengen AL, Anderson P, Gjersoe E, et al.  Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scandinavian Journal of Primary Health Care. 1992;10:142
  89. Cardozo LD, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. British Journal of Obstetrics and Gynaecology. 1998;105:403–407
  90. Eriksen B. A randomized, open, parallel-group study on the preventitive effect of an oestradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology. 1999;180:1072–1079
  91. Park WC, Jordan VC. Selective oestrogen receptor modulators (SERMS) and their roles in cancer prevention. Trends in Molecular Medicine. 2002;8:82–88
  92. Silfen SL, Ciaccia AV, Bryant HU. Selective oestrogen receptor modulators: tissue selectivity and differential uterine effects. Climacteric. 1999;ii:268–283
  93. Hendrix SL, McNeeley SG. Effect of selective oestrogen receptor modulators on reproductive tissues other than endometrium. Annals of the New York Academy of Sciences. 2001;949:243–250
  94. Goldstein SR, Neven P, Zhou L, et al.  Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstetrics and Gynaecology. 2001;98:91–96

PII: S1521-690X(02)00085-4

doi: 10.1016/S1521-690X(02)00085-4

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 91-104 , March 2003

Article Tools